Novavax Cashes In On Its COVID Albatross -- Challenges Remain (Rating Upgrade)
I have been warning about Novavax's risks since 2016, highlighting its ongoing struggles with the FDA. Novavax's Q3 2024 earnings call and 10-Q reveal a collaboration negotiated from a position of relative weakness. The partnership with Sanofi …